Genprex, Inc. (0A8I.L)

2.2750 +0.1049 (+4.83%) At close: 02:55PM BST

Genprex, Inc.

3300 Bee Cave Road
Suite 650-227
Austin, TX 78746
United States
877 774 4679
https://www.genprex.com

Sector(s): 
Industry: 
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John Rodney Varner	Co-Founder, Chairman, President & CEO	612.21k	N/A	1957
Dr. Mark S. Berger M.D.	Chief Medical Officer	528.16k	N/A	1955
Mr. Ryan M. Confer M.S.	Chief Financial Officer	606.57k	N/A	1982
Mr. David M. Schloss	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Thomas C. Gallagher Esq.	Senior Vice President of Intellectual Property & Licensing	N/A	N/A	N/A
Dr. Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A
Dr. Jack A. Roth F.A.C.S., M.D.	Chairman of Scientific & Medical Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Corporate governance

Genprex, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.